Noxilizer is licensing its proprietary nitrogen dioxide technology. STG will be responsible for the development, manufacturing and commercialization of this product line.
Isolators and other related enclosures are an important part of any life science company's manufacturing and research and development process. The closed areas are used to produce products in a decontaminated environment. Examples of products include: prefilled syringes and insulin vials. Sterilant generators were developed in the late 1980's to provide more effective decontamination. Today, the STERIS Corporation (Mentor, OH) and Skan AG (Switzerland) are the leading companies in the isolator decontamination generator market. Both companies utilize hydrogen peroxide.
“This licensing agreement further validates Noxilizer's technology and its importance in solving challenges of infection control and decontamination. The Noxilizer team is excited to work with STG as we grow our business in the important isolator market,” says Lawrence Bruder, President & CEO of Noxilizer, Inc.
“As a 30-year veteran of this industry, I see real advantages that the Noxilizer technology has over the current process options. We believe customers will value the faster aeration time and improved material compatibility,” states Michael Ferguson, Business Director of STG.
A sterilant generator is in the development stage and will go through additional testing this year. Potential customers include: pharmaceutical and biotech companies, research and development, manufacturing and quality control groups.
Isolators and other related enclosures are an important part of any life science company's manufacturing and research and development process. The closed areas are used to produce products in a decontaminated environment. Examples of products include: prefilled syringes and insulin vials. Sterilant generators were developed in the late 1980's to provide more effective decontamination. Today, the STERIS Corporation (Mentor, OH) and Skan AG (Switzerland) are the leading companies in the isolator decontamination generator market. Both companies utilize hydrogen peroxide.
“This licensing agreement further validates Noxilizer's technology and its importance in solving challenges of infection control and decontamination. The Noxilizer team is excited to work with STG as we grow our business in the important isolator market,” says Lawrence Bruder, President & CEO of Noxilizer, Inc.
“As a 30-year veteran of this industry, I see real advantages that the Noxilizer technology has over the current process options. We believe customers will value the faster aeration time and improved material compatibility,” states Michael Ferguson, Business Director of STG.
A sterilant generator is in the development stage and will go through additional testing this year. Potential customers include: pharmaceutical and biotech companies, research and development, manufacturing and quality control groups.
Companies in this press-release
